Open main menu

HemOnc.org - A Hematology Oncology Wiki β

ERBB3 (HER3)

1 regimens on this page
1 variants on this page


Contents

All lines of therapy

Neratinib monotherapy

back to top

Regimen

Study Evidence
Hyman et al. 2018 (SUMMITHER) Non-randomized basket trial, <20 pts in this subgroup

Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.

Biomarker eligibility criteria

  • Gene: HER3
  • Alteration: various substitutions
  • Acceptable methods of measurement: next-generation sequencing assay or RT-PCR, Sanger, pyrosequencing, or mass spectrometry-based sequencing methods

Preceding treatment

  • No prior treatment with HER kinase inhibitors

Chemotherapy

Supportive medications

28-day cycles

References

  1. SUMMIT: Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. link to original article contains verified protocol link to PMC article PubMed